Loading
A phase 1/2 trial of Pembrolizumab, Pemetrexed, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Inhibrx Biosciences, Inc, now recruiting.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) is a phase 1/2 interventional study registered as NCT04198766 by Inhibrx Biosciences, Inc, with 340 participants planned, started 2019-12-10 and due to reach its primary completion in 2033-07. Interventions recorded: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/